Shots:
- Kaken to receive an up front in cash and is eligible to receive milestones and royalties on the sales of the product. Almirall plans to have a pre-submission meeting with regulatory authorities in next year to prepare the approval of the product in the EU
- Almirall get the exclusive rights for the development and commercialization of the topical antifungal formulation of efinaconazole in the EU
- Efinaconazole is a triazole antifungal therapy indicated for the treatment of fungal infection of the nail called onychomycosis
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post Almirall and Kaken Enter into a License Agreement for the Development and Commercialization of Efinaconazole in Europe first appeared on PharmaShots.
